Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | OGG1 | O15527 | 1/20 | 0.48 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7363838 | 0.83 | KMT2A (0.59) | RAB9ANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL16321463 | 0.83 | CYP11B1 (0.53) | TP53RAB9ANPC1MAPK1KMT2A | |
| SCHEMBL28954065 | 0.81 | RAB9A (0.71) | RAB9ANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL30240066 | 0.81 | RAB9A (0.71) | RAB9ANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL3599836 | 0.81 | HDAC1 (0.47) | TP53RAB9ANPC1MAPK1KMT2A | |
| SCHEMBL3599830 | 0.80 | HDAC1 (0.46) | TP53RAB9ANPC1MAPK1KMT2A | |
| SCHEMBL14893346 | 0.79 | ALDH1A1 (0.63) | RAB9ANPC1MAPK1KMT2AMEN1 | |
| SCHEMBL3599833 | 0.79 | MEN1 (0.46) | TP53RAB9ANPC1MAPK1KMT2A | |
| SCHEMBL2149170 | 0.79 | MEN1 (0.46) | TP53RAB9ANPC1MAPK1KMT2A | |
| SCHEMBL14893327 | 0.78 | ALDH1A1 (0.54) | RAB9ANPC1KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790231-B2 | Chromane and chromene derivatives and their use as CRAC modulators | LUPIN LIMITED (IN) | 2017-10-17 | — | — | US | disclosed |
| US-9790231-B2 | Chromane and chromene derivatives and their use as CRAC modulators | LUPIN LIMITED (IN) | 2017-10-17 | — | — | US | disclosed |
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-9399638-B2 | Substituted pyridine compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-07-26 | — | — | US | disclosed |
| US-9399638-B2 | Substituted pyridine compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-07-26 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
| EP-3013810-A1 | CHROMANE AND CHROMENE DERIVATIVES AND THEIR USE AS CRAC MODULATORS | Lupin Limited (IN) | 2016-05-04 | — | — | EP | disclosed |
| EP-3010586-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | Lupin Limited (IN) | 2016-04-27 | — | — | EP | disclosed |
| US-20150111900-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
| US-20150111900-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
| EP-2844655-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | Lupin Limited (IN) | 2015-03-11 | — | — | EP | disclosed |
| WO-2014207648-A1 | CHROMANE AND CHROMENE DERIVATIVES AND THEIR USE AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014207648-A1 | CHROMANE AND CHROMENE DERIVATIVES AND THEIR USE AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014203217-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014203217-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2014-12-24 | — | — | WO | disclosed |
| WO-2013164769-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2013-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111900-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | TP53 4101/4885RAB9A 963/4885NPC1 954/4885 |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | RYR2, NR2C2, CACNA1E | TP53 3651/4885RAB9A 1720/4885NPC1 1879/4885 |
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | TP53 4101/4885RAB9A 963/4885NPC1 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.